MA35275B1 - Composés de tétrahydropyridopyridine et tétrahydropyridopyrimidine et utilisation de ceux-ci en tant que modulateurs de récepteur c5a - Google Patents
Composés de tétrahydropyridopyridine et tétrahydropyridopyrimidine et utilisation de ceux-ci en tant que modulateurs de récepteur c5aInfo
- Publication number
- MA35275B1 MA35275B1 MA36696A MA36696A MA35275B1 MA 35275 B1 MA35275 B1 MA 35275B1 MA 36696 A MA36696 A MA 36696A MA 36696 A MA36696 A MA 36696A MA 35275 B1 MA35275 B1 MA 35275B1
- Authority
- MA
- Morocco
- Prior art keywords
- compounds
- tetrahydropyridopyridine
- tetrahydropyridopyrimidine
- receptor modulators
- present
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Ophthalmology & Optometry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Transplantation (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne un composé de formule i : (i) un procédé pour fabriquer les composés de l'invention, et ses utilisations thérapeutiques. La présente invention concerne en outre une combinaison d'agents pharmacologiquement actifs et une composition pharmaceutique.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161510643P | 2011-07-22 | 2011-07-22 | |
US201161539732P | 2011-09-27 | 2011-09-27 | |
PCT/US2012/047617 WO2013016197A1 (fr) | 2011-07-22 | 2012-07-20 | Composés de tétrahydropyridopyridine et tétrahydropyridopyrimidine et utilisation de ceux-ci en tant que modulateurs de récepteur c5a |
Publications (1)
Publication Number | Publication Date |
---|---|
MA35275B1 true MA35275B1 (fr) | 2014-07-03 |
Family
ID=46604083
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA36696A MA35275B1 (fr) | 2011-07-22 | 2014-01-20 | Composés de tétrahydropyridopyridine et tétrahydropyridopyrimidine et utilisation de ceux-ci en tant que modulateurs de récepteur c5a |
Country Status (25)
Country | Link |
---|---|
US (2) | US8846656B2 (fr) |
EP (1) | EP2734521B1 (fr) |
JP (1) | JP6040237B2 (fr) |
KR (1) | KR20140096020A (fr) |
CN (1) | CN103814027B (fr) |
AP (1) | AP2014007398A0 (fr) |
AR (1) | AR087288A1 (fr) |
AU (1) | AU2012287183B2 (fr) |
BR (1) | BR112014001468A2 (fr) |
CA (1) | CA2842528A1 (fr) |
CL (1) | CL2014000171A1 (fr) |
CO (1) | CO6862157A2 (fr) |
CR (1) | CR20140032A (fr) |
EA (1) | EA201490320A1 (fr) |
ES (1) | ES2637167T3 (fr) |
IL (1) | IL230501A0 (fr) |
MA (1) | MA35275B1 (fr) |
MX (1) | MX336497B (fr) |
PE (1) | PE20141281A1 (fr) |
PL (1) | PL2734521T3 (fr) |
PT (1) | PT2734521T (fr) |
TN (1) | TN2014000030A1 (fr) |
TW (1) | TW201311688A (fr) |
UY (1) | UY34209A (fr) |
WO (1) | WO2013016197A1 (fr) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012035078A1 (fr) * | 2010-09-16 | 2012-03-22 | Novartis Ag | Inhibiteurs de la 17α-hydroxylase/c17,20-lyase |
WO2012088266A2 (fr) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Imidazopyridazines et benzimidazoles substitués en tant qu'inhibiteurs de fgfr3 |
US8846656B2 (en) | 2011-07-22 | 2014-09-30 | Novartis Ag | Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators |
EA027113B1 (ru) * | 2012-05-04 | 2017-06-30 | Новартис Аг | Регуляторы пути комплемента и их применение |
US9056874B2 (en) | 2012-05-04 | 2015-06-16 | Novartis Ag | Complement pathway modulators and uses thereof |
CN107383009B (zh) | 2012-06-13 | 2020-06-09 | 因塞特控股公司 | 作为fgfr抑制剂的取代的三环化合物 |
WO2014026125A1 (fr) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Dérivés de pyrazine en tant qu'inhibiteurs de fgfr |
US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
JP6387391B2 (ja) * | 2013-03-14 | 2018-09-05 | ノバルティス アーゲー | 眼科疾患の処置に有用な補体因子B阻害剤としての2−(1H−インドール−4−イルメチル)−3H−イミダゾ[4,5−b]ピリジン−6−カルボニトリル誘導体 |
SG11201508328PA (en) | 2013-04-19 | 2015-11-27 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
WO2015061693A1 (fr) | 2013-10-24 | 2015-04-30 | Trustees Of Boston University | Système de perfusion faisant appel à un ensemble perfusion destiné à prévenir les erreurs de canalisation en cas de multiples médicaments |
US9676728B2 (en) | 2013-10-30 | 2017-06-13 | Novartis Ag | 2-benzyl-benzimidazole complement factor B inhibitors and uses thereof |
TWI700283B (zh) | 2014-08-04 | 2020-08-01 | 德商拜耳製藥公司 | 2-(嗎啉-4-基)-1,7-萘啶 |
US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
WO2016107832A1 (fr) | 2014-12-30 | 2016-07-07 | F. Hoffmann-La Roche Ag | Nouvelles tétrahydropyridopyrimidines et tétrahydropyridopyridines pour le traitement et la prévention d'une infection par le virus de l'hépatite b |
WO2016134294A1 (fr) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
CN107438607B (zh) | 2015-02-20 | 2021-02-05 | 因赛特公司 | 作为fgfr抑制剂的双环杂环 |
US10898487B2 (en) | 2016-12-22 | 2021-01-26 | Boehringer Ingelheim International Gmbh | Benzylamino substituted quinazolines and derivatives as SOS1 inhibitors |
AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
ES2934507T3 (es) | 2017-05-31 | 2023-02-22 | Chemocentryx Inc | Anillos fusionados en 5-5 como inhibidores de C5a |
US10562896B2 (en) * | 2017-05-31 | 2020-02-18 | Chemocentryx, Inc. | 6-5 fused rings as C5a inhibitors |
TWI810230B (zh) | 2017-12-21 | 2023-08-01 | 德商百靈佳殷格翰國際股份有限公司 | 作為sos1抑制劑之新穎芐胺基取代吡啶并嘧啶酮及衍生物 |
WO2019126424A1 (fr) | 2017-12-22 | 2019-06-27 | Chemocentryx, Inc. | Composés cycliques condensés 6,5 à substitution diaryle, utilisés en tant qu'inhibiteurs du c5ar |
JP7253557B2 (ja) | 2017-12-22 | 2023-04-06 | ケモセントリックス,インコーポレイティド | C5aR阻害剤としてのジアリール置換5,5-縮合環化合物 |
HUE060515T2 (hu) * | 2018-01-10 | 2023-03-28 | Idorsia Pharmaceuticals Ltd | 2,4,6,7-Tetrahidro-pirazolo[4,3-d]pirimidin-5-on származékok és rokon vegyületek mint C5A receptor modulátorok vasculitis és gyulladásos betegségek kezelésére |
IL277608B2 (en) | 2018-04-02 | 2023-09-01 | Chemocentryx Inc | Prodrugs of conjugated c5ar antagonists |
CA3099116A1 (fr) | 2018-05-04 | 2019-11-07 | Incyte Corporation | Sels d'un inhibiteur de fgfr |
AU2019262195B2 (en) | 2018-05-04 | 2024-09-12 | Incyte Corporation | Solid forms of an FGFR inhibitor and processes for preparing the same |
US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
WO2021007269A1 (fr) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr |
JP2022552324A (ja) | 2019-10-14 | 2022-12-15 | インサイト・コーポレイション | Fgfr阻害剤としての二環式複素環 |
US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
CA3163875A1 (fr) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Heterocycles tricycliques en tant qu'inhibiteurs de fgfr |
KR20220131900A (ko) | 2019-12-04 | 2022-09-29 | 인사이트 코포레이션 | Fgfr 억제제의 유도체 |
WO2021146424A1 (fr) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr |
CN115768750A (zh) * | 2020-02-17 | 2023-03-07 | 阿莱斯塔治疗公司 | Gcn2调节剂化合物 |
KR20230022402A (ko) * | 2020-04-29 | 2023-02-15 | 릴레이 테라퓨틱스, 인크. | PI3Kα 억제제 및 이의 사용 방법 |
EP4214204A1 (fr) | 2020-09-18 | 2023-07-26 | Bayer Aktiengesellschaft | Pyrido[2,3-d]pyrimidin-4-amines en tant qu'inhibiteurs de sos1 |
US20230382856A1 (en) * | 2020-10-30 | 2023-11-30 | Daiichi Sankyo Company, Limited | Method of producing 3-methyl-4-halo-indole derivative |
US12065494B2 (en) | 2021-04-12 | 2024-08-20 | Incyte Corporation | Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent |
EP4074317A1 (fr) | 2021-04-14 | 2022-10-19 | Bayer AG | Dérivés de phosphore en tant que nouveaux inhibiteurs de sos1 |
JP2024522189A (ja) | 2021-06-09 | 2024-06-11 | インサイト・コーポレイション | Fgfr阻害剤としての三環式ヘテロ環 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT72878B (en) | 1980-04-24 | 1983-03-29 | Merck & Co Inc | Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents |
US4727149A (en) | 1982-03-11 | 1988-02-23 | John Wyeth & Brother Limited | Preparation of nitriles of fused ring pyridine derivatives |
US5853740A (en) | 1996-08-07 | 1998-12-29 | Abbott Laboratories | Delivery system for pharmaceutical agents encapsulated with oils |
US6638926B2 (en) | 2000-09-15 | 2003-10-28 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
AU2003253130A1 (en) | 2002-08-19 | 2004-03-03 | Glenmark Pharmaceuticals Limited | Condensed heterocyclic compounds as pde-iv inhibitors for the treatment of inflammatory and allergic disorders |
EP1631260A2 (fr) | 2003-02-28 | 2006-03-08 | Transform Pharmaceuticals, Inc. | Compositions pharmaceutiques a base d'un co-cristal |
JP2006521398A (ja) | 2003-03-28 | 2006-09-21 | サイオス・インコーポレーテツド | TGFβの二−環式ピリミジン阻害剤 |
BRPI0409211A (pt) | 2003-04-18 | 2006-03-28 | Lilly Co Eli | composto, composição farmacêutica, métodos para ativar receptores 5-ht1f, para inibir extravasão de proteìna neuronial, e para o tratamento ou prevenção de enxaqueca em um mamìfero, e, uso de um composto |
EP1663994B1 (fr) * | 2003-08-05 | 2012-03-07 | Vertex Pharmaceuticals Incorporated | Composes de tetrahydroquinazoline utilises comme inhibiteurs de canaux ioniques potentiel-dependants |
GB0403038D0 (en) | 2004-02-11 | 2004-03-17 | Novartis Ag | Organic compounds |
AU2005244104B2 (en) | 2004-05-08 | 2012-03-15 | Novartis International Pharmaceutical Ltd. | 4,5-disubstituted-2-aryl pyrimidines |
US7429666B2 (en) | 2004-06-10 | 2008-09-30 | Merck Frosst Canada Ltd. | Pyridine analogs as C5a antagonists |
TW200626157A (en) | 2004-09-30 | 2006-08-01 | Tibotec Pharm Ltd | HCV inhibiting bi-cyclic pyrimidines |
CN102627640A (zh) | 2005-08-12 | 2012-08-08 | 默沙东公司 | 可用作p38激酶抑制剂的杂二环化合物 |
AU2007242883B2 (en) | 2006-04-20 | 2012-09-27 | F. Hoffmann-La Roche Ag | Diazepan derivatives modulators of chemokine receptors |
JP2009534454A (ja) | 2006-04-25 | 2009-09-24 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
US8563566B2 (en) | 2007-08-01 | 2013-10-22 | Valeant Pharmaceuticals International | Naphthyridine derivatives as potassium channel modulators |
US20090048295A1 (en) | 2007-08-13 | 2009-02-19 | Joseph Kent Barbay | Substituted 5,6,7,8-tetrahydroquinoline derivatives, compositions, and methods of use thereof |
AR073354A1 (es) | 2008-07-31 | 2010-11-03 | Genentech Inc | Compuestos de pirimidina, composiciones farmaceuticas y su uso en el tratamiento del cancer. |
WO2010028174A1 (fr) | 2008-09-03 | 2010-03-11 | Dr. Reddy's Laboratories Ltd. | Nouveaux composés bicycliques comme modulateurs de gata |
AR073304A1 (es) | 2008-09-22 | 2010-10-28 | Jerini Ag | Moduladores del receptor de bradiquinina b2 de molecula pequena |
WO2010120994A2 (fr) | 2009-04-17 | 2010-10-21 | Wyeth Llc | Composés d'uréido-aryl-pyrimidine et de carbamoylaryl-morpholino-pyrimidine, leur utilisation comme inhibiteurs de la kinase mtor et de la kinase pi-3, et leur synthèse |
US20120244192A1 (en) | 2009-04-27 | 2012-09-27 | Cook Gary P | Sustained release formulations of peptidomimetic drugs and uses thereof |
EP2434885B1 (fr) | 2009-05-27 | 2014-03-26 | Merck Sharp & Dohme Corp. | Inhibiteurs de pde10 à l'alcoxy tétrahydro-pyridopyrimidine |
EP2467382B1 (fr) | 2009-08-17 | 2014-06-25 | Merck Sharp & Dohme Corp. | Amino-tétrahydro-pyridopyrimidine inhibiteurs de pde10 |
JP2013032290A (ja) | 2009-11-20 | 2013-02-14 | Dainippon Sumitomo Pharma Co Ltd | 新規縮合ピリミジン誘導体 |
US8846656B2 (en) | 2011-07-22 | 2014-09-30 | Novartis Ag | Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators |
US20140227321A1 (en) | 2011-09-30 | 2014-08-14 | Kineta, Inc. | Anti-viral compounds |
US10220002B2 (en) | 2011-12-02 | 2019-03-05 | Board Of Regents Of The University Of Nebraska | Controlled-release peptide compositions and uses thereof |
-
2012
- 2012-07-19 US US13/553,120 patent/US8846656B2/en not_active Expired - Fee Related
- 2012-07-20 PE PE2014000114A patent/PE20141281A1/es not_active Application Discontinuation
- 2012-07-20 EA EA201490320A patent/EA201490320A1/ru unknown
- 2012-07-20 BR BR112014001468A patent/BR112014001468A2/pt not_active Application Discontinuation
- 2012-07-20 AP AP2014007398A patent/AP2014007398A0/xx unknown
- 2012-07-20 PL PL12743023T patent/PL2734521T3/pl unknown
- 2012-07-20 JP JP2014521829A patent/JP6040237B2/ja not_active Expired - Fee Related
- 2012-07-20 PT PT127430239T patent/PT2734521T/pt unknown
- 2012-07-20 TW TW101126407A patent/TW201311688A/zh unknown
- 2012-07-20 CA CA2842528A patent/CA2842528A1/fr not_active Abandoned
- 2012-07-20 UY UY0001034209A patent/UY34209A/es not_active Application Discontinuation
- 2012-07-20 CN CN201280045758.6A patent/CN103814027B/zh not_active Expired - Fee Related
- 2012-07-20 KR KR1020147004232A patent/KR20140096020A/ko not_active Application Discontinuation
- 2012-07-20 AU AU2012287183A patent/AU2012287183B2/en not_active Ceased
- 2012-07-20 ES ES12743023T patent/ES2637167T3/es active Active
- 2012-07-20 MX MX2014000898A patent/MX336497B/es unknown
- 2012-07-20 WO PCT/US2012/047617 patent/WO2013016197A1/fr active Application Filing
- 2012-07-20 EP EP12743023.9A patent/EP2734521B1/fr active Active
- 2012-07-23 AR ARP120102669A patent/AR087288A1/es unknown
-
2014
- 2014-01-16 IL IL230501A patent/IL230501A0/en unknown
- 2014-01-20 MA MA36696A patent/MA35275B1/fr unknown
- 2014-01-20 TN TNP2014000030A patent/TN2014000030A1/en unknown
- 2014-01-22 CR CR20140032A patent/CR20140032A/es unknown
- 2014-01-22 CL CL2014000171A patent/CL2014000171A1/es unknown
- 2014-01-24 CO CO14014580A patent/CO6862157A2/es active IP Right Grant
- 2014-08-08 US US14/455,848 patent/US9505755B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN103814027A (zh) | 2014-05-21 |
KR20140096020A (ko) | 2014-08-04 |
AU2012287183A1 (en) | 2014-01-30 |
US20140349995A1 (en) | 2014-11-27 |
PE20141281A1 (es) | 2014-09-24 |
US8846656B2 (en) | 2014-09-30 |
IL230501A0 (en) | 2014-03-31 |
BR112014001468A2 (pt) | 2017-01-10 |
CL2014000171A1 (es) | 2014-10-03 |
AR087288A1 (es) | 2014-03-12 |
UY34209A (es) | 2013-02-28 |
US20130184253A1 (en) | 2013-07-18 |
CO6862157A2 (es) | 2014-02-10 |
EP2734521A1 (fr) | 2014-05-28 |
ES2637167T3 (es) | 2017-10-11 |
PL2734521T3 (pl) | 2017-10-31 |
JP2014521607A (ja) | 2014-08-28 |
EP2734521B1 (fr) | 2017-05-10 |
CN103814027B (zh) | 2016-07-06 |
TW201311688A (zh) | 2013-03-16 |
JP6040237B2 (ja) | 2016-12-07 |
CR20140032A (es) | 2014-05-16 |
AP2014007398A0 (en) | 2014-01-31 |
WO2013016197A1 (fr) | 2013-01-31 |
MX2014000898A (es) | 2014-02-19 |
AU2012287183B2 (en) | 2014-11-20 |
US9505755B2 (en) | 2016-11-29 |
MX336497B (es) | 2016-01-21 |
TN2014000030A1 (en) | 2015-07-01 |
EA201490320A1 (ru) | 2014-06-30 |
CA2842528A1 (fr) | 2013-01-31 |
PT2734521T (pt) | 2017-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA35275B1 (fr) | Composés de tétrahydropyridopyridine et tétrahydropyridopyrimidine et utilisation de ceux-ci en tant que modulateurs de récepteur c5a | |
MA37477A1 (fr) | Modulateurs des voies du complément et leurs utilisations | |
MA33358B1 (fr) | Arylpyridine en tant qu'inhibiteurs de l'aldostérone synthase | |
MA42678B1 (fr) | Nouveaux analogues nucléosidiques substitués à cycle aromatique bicyclique 6-6 pour une utilisation en tant qu'inhibiteurs de prmt5 | |
MA34837B1 (fr) | Composés indoliques ou analogues de ceux-ci utiles dans le traitement de la dégénérescence maculaire liée à l'âge (dmla) | |
MA46101B1 (fr) | Modulateurs allostériques positifs du récepteur muscarinique m1 | |
MA35576B1 (fr) | Nouveaux composés | |
MA35753B1 (fr) | Aryl-dihydropyridinones et pipéridinones en tant qu'inhibiteurs de mgat2 | |
MA34644B1 (fr) | Dérivés de pyrazole aminopyrimidine en tant que modulateurs du lrrk2 | |
MA38330B1 (fr) | Dérivés d'acide phosphonique butanoïque de bisphénol substitués en qualité d'inhibiteurs de nep (endopeptidase neutre) | |
MA34078B1 (fr) | Derives d'arylethynyle | |
MA35128B1 (fr) | Nouveaux dérivés d'imidazole utiles pour le traitement de l'arthrite | |
MA35032B1 (fr) | Derives de glycoside et leurs utilisations dans le traitement du diabete | |
MA33636B1 (fr) | Dérivés aminopropioniques substitués comme inhibiteurs de néprilysine | |
MA37886B1 (fr) | Nouvelles pyridinones bicycliques | |
MX2014013428A (es) | Moduladores de la ruta del complemento y usos de los mismos. | |
MA38112B1 (fr) | Dérivés d'imidazopyridazine en tant que modulateurs d'un récepteur gabaa | |
MA38865A1 (fr) | Formulation comprenant un agent hypolipidémiant | |
MA39983B1 (fr) | Dérivés de carboxamide | |
MA39152B1 (fr) | Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d'orexine | |
MA37501B1 (fr) | Composés de pyrazole utilisés en tant qu'inhibiteurs de sglt1 | |
MA38410B1 (fr) | Composés d'azétidinyloxyphénylpyrrolidine | |
MA38679B1 (fr) | Modulateurs du récepteur de cxcr7 | |
MA34578B1 (fr) | Composés de tétrahydrofuranyl disubstitués en tant qu'antagonistes du récepteur de la bradykinine b1 | |
MA35196B1 (fr) | Dérivés de 2-amino-3-(inidazol-2-yl)-pyridine-4-one et utilisation de ceux-ci comme inhibiteurs de kinases associées au récepteur du vegf |